Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

NHS England, Biogen reach deal on pricey drug for deadly disorder

England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.

Read More »

Novartis vows to fight U.S. price-fixing claims against Sandoz unit

Novartis said claims of price fixing against the drugmaker’s Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit.

Read More »

Lilly’s new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.

Read More »

Trump slams drugmakers, vows to let U.S. states buy cheaper medicines abroad

U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs and vowed to allow U.S. states to buy medicines from other countries if they cost less.

Read More »

U.S. finalizes rule requiring drug prices in TV spots

The Trump administration will require drugmakers to disclose the list price of prescription drugs in DTC TV advertisements, part of the government’s efforts to lower costs for U.S. consumers.

Read More »

Amgen sets $21,900 annual price for new Evenity bone drug

Amgen Inc. set the U.S. list price for the company’s new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

Read More »

ViiV Healthcare Announces 3-Year HIV Data for Juluca 2-Drug Combo

ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.

Read More »

Bayer, J&J settle U.S. Xarelto litigation for $775 million

Bayer AG and Johnson & Johnson agreed to settle more than 25,000 U.S. lawsuits over the companies’ blockbuster blood thinner Xarelto for a total of $775 million, court documents showed.

Read More »

AbbVie’s Humira Remains Top-Selling Rx Drug for 2018

AbbVie’s Humira, the world’s top-selling prescription medicine since 2012, brought the Illinois-based company nearly $20 billion in revenue in 2018.

Read More »

Eli Lilly seeks to quell drug price anger with cheaper insulin

Drugmaker Eli Lilly and Co. announced plans to sell a half-price version of the company’s popular insulin injection Humalog.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom